Drug Trial Radar · NCT00002599
Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma
Last checked: Nov 20, 2026Latest source record: Dec 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
750
Planned (sponsor's estimate)
Start
Sep 1994
Primary completion
Not stated
Sponsor
- Lead sponsor
- Medical Research CouncilGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- May 21, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining bone marrow or peripheral stem cell transplantation with chemotherapy may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether a more intensive chemotherapy regimen plus stem cell or bone marrow transplant is more effective than standard chemotherapy in treating patients with myeloma. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of combination chemotherapy plus interferon alfa with or without high dose melphalan or bone marrow or peripheral stem cell transplantation in treating patients with previously untreated myeloma.
Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastimBiological
recombinant interferon alfaBiological
sargramostimBiological
carmustineDrug
cyclophosphamideDrug
doxorubicin hydrochlorideDrug
melphalanDrug
methylprednisoloneDrug
prednisoneDrug
vincristine sulfateDrug
low-LET cobalt-60 gamma ray therapyRadiation
low-LET photon therapyRadiation
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Leeds Teaching Hospital Trust
Leeds, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.